



National  
Comprehensive  
Cancer  
Network®

**NCCN Clinical Practice Guidelines in Oncology™**

# **Bladder Cancer**

Including Upper Tract Tumors and  
Urothelial Carcinoma of the Prostate

V.1.2007

**Continue**

[www.nccn.org](http://www.nccn.org)

## NCCN Bladder Cancer Panel Members

\*James E. Montie, MD/Chair <sup>⊖</sup>  
University of Michigan Comprehensive Cancer  
Center

Neil A. Abrahams, MD <sup>≠</sup>  
UNMC Eppley Cancer Center at The Nebraska  
Medical Center

Robert R. Bahnson, MD <sup>⊖</sup>  
Arthur G. James Cancer Hospital & Richard J.  
Solove Research Institute at The Ohio State  
University

Mario A. Eisenberger, MD <sup>† ⊖</sup>  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

Rizk El-Galley, MD <sup>⊖</sup>  
University of Alabama at Birmingham  
Comprehensive Cancer Center

Harry W. Herr, MD <sup>⊖</sup>  
Memorial Sloan-Kettering Cancer Center

Gary R. Hudes, MD <sup>† ‡</sup>  
Fox Chase Cancer Center

\*Timothy M. Kuzel, MD <sup>‡</sup>  
Robert H. Lurie Comprehensive Cancer Center  
of Northwestern University

Paul H. Lange, MD <sup>⊖</sup>  
Fred Hutchinson Cancer Research  
Center/Seattle Cancer Care Alliance

Anthony Patterson, MD <sup>⊖</sup>  
St. Jude Children's Research Hospital/University  
of Tennessee Cancer Institute

\* Alan Pollack, MD, PhD <sup>§</sup>  
Fox Chase Cancer Center

Jerome P. Richie, MD <sup>⊖</sup>  
Dana-Farber/Partners CancerCare

Wade J. Sexton, MD <sup>⊖</sup>  
H. Lee Moffitt Cancer Center & Research Institute  
at the University of South Florida

\* William U. Shipley, MD <sup>§ ⊖</sup>  
Massachusetts General Hospital

Eric J. Small, MD <sup>† ⊖</sup>  
UCSF Comprehensive Cancer Center

Donald L. Trump, MD <sup>†</sup>  
Roswell Park Cancer Institute

Phillip J. Walther, MD, PhD <sup>⊖</sup>  
Duke Comprehensive Cancer Center

Timothy G. Wilson, MD <sup>⊖</sup>  
City of Hope Cancer Center

⊖ Urology  
≠ Pathology  
† Medical oncology  
‡ Hematology/Hematology oncology  
§ Radiotherapy/Radiation oncology  
\* Writing committee member

**Continue**

## Table of Contents

### [NCCN Bladder Cancer Panel Members](#)

#### Bladder Cancer:

- [Clinical Presentation and Workup \(BL-1\)](#)
- [Noninvasive or CIS, Primary Treatment \(BL-1\)](#)
  - ▶ [Adjuvant Treatment and Follow-up \(BL-2\)](#)
  - ▶ [Recurrent or Persistent Disease \(BL-3\)](#)
- [Muscle Invasive or Metastatic, Primary and Adjuvant Treatment \(BL-1\)](#)
  - ▶ [Follow-up, Recurrent Disease \(BL-7\)](#)
- [Principles of Surgical Management \(BL-A\)](#)
- [Probability of Recurrence and Progression \(BL-B\)](#)
- [Non-Urothelial Cell Carcinoma of the Bladder \(BL-C\)](#)
- [Principles of Chemotherapy Management \(BL-D\)](#)
- [Principles of Radiation Management of Invasive Disease \(BL-E\)](#)
- [Principles of Pathology Management \(BL-F\)](#)

#### Upper Tract Tumors:

- [Renal Pelvis \(UTT-1\)](#)
- [Ureter \(UTT-2\)](#)

### [Urothelial Carcinoma of the Prostate \(UCP-1\)](#)

#### [Guidelines Index](#)

#### [Print the Bladder Cancer Guideline](#)

#### [Order the Patient Version of the](#)

#### [Bladder Cancer Guidelines](#)

These guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2006.

**[For help using these documents, please click here](#)**

#### [Staging](#)

#### [Manuscript](#)

#### [References](#)

**Clinical Trials:** The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, [click here: nccn.org/clinical\\_trials/physician.html](#)

**NCCN Categories of Consensus:** All recommendations are Category 2A unless otherwise specified.

See [NCCN Categories of Consensus](#)

### **[Summary of Guidelines Updates](#)**


## Summary of the Guidelines updates

Summary of the changes in the v.1.2007 version of the Bladder Cancer guidelines from the v.1.2006 version include:

- Ureteroscopy and cytology of upper tract were added as considerations for cytology positive and imaging and cystoscopy negative disease ([BL-3](#)).
- A footnote was added to say that BCG + interferon has been reported to be effective for recurrent or persistent disease, but data from Phase III trials are not available ([BL-3](#)).
- Clinical trial was added as an option for recurrent disease with incomplete response to BCG ([BL-3](#)).
- Primary treatment for cT2 patients was reworded ([BL-4](#)).
- For patients with cT3 and negative nodes with extensive comorbid disease or poor performance status, TURBT, RT, chemotherapy were added as treatment options ([BL-5](#)).
- The term “salvage” was removed from treatment of recurrence ([BL-7](#)).
- Imaging of upper tracts and abdomen was added for recurrence every 3-6 months for 2 years, then as clinically indicated ([BL-7](#)).
- Carboplatin/paclitaxel deleted as a newer alternative chemotherapy regimen, while gemcitabine/docetaxel or paclitaxel, and cisplatin/gemcitabine/paclitaxel or docetaxel were added ([BL-D](#)).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




<sup>a</sup>Imaging may include IVP, CT urography, renal ultrasound with retrograde pyelogram, or MRI urogram.

<sup>b</sup>See [Principles of Surgical Management \(BL-A\)](#).

<sup>c</sup>The modifier "c" refers to clinical staging based on bimanual examination under anesthesia and endoscopic surgery (biopsy or transurethral resection) and imaging studies. The modifier "p" refers to pathologic staging based on cystectomy and lymph node dissection.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



<sup>b</sup>See Principles of Surgical Management (BL-A).

<sup>c</sup>The modifier “c” refers to clinical staging based on bimanual examination under anesthesia and endoscopic surgery (biopsy or transurethral resection) and imaging studies. The modifier “p” refers to pathologic staging based on cystectomy and lymph node dissection.

<sup>d</sup>Grading of these protocols refers to the World Health Organization International Histological Classification of Tumours, Edition 1, published 1973.

<sup>e</sup>See Probability of Recurrence and Progression (BL-B) and Non-Urothelial Cell Carcinoma (UCC) of the Bladder (BL-C).

<sup>f</sup>Indications for adjuvant therapy: Based on probability of recurrence and progression to muscle invasive disease: (1) size; (2) number; (3) grade.

<sup>g</sup>Immediate intravesical chemotherapy, not immunotherapy, may decrease recurrence.


<sup>h</sup>Imaging may include IVP, CT urography, retrograde pyelogram, or MRI urogram.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

POSTTREATMENT Ta, T1, CIS  
PERSISTANT OR RECURRENT DISEASE

TREATMENT OF RECURRENT/PERSISTENT DISEASE




<sup>b</sup> See Principles of Surgical Management (BL-A).

<sup>f</sup> Indications for adjuvant therapy: Based on probability of recurrence and progression to muscle invasive disease: (1) size; (2) number; (3) grade.

<sup>i</sup> BCG + interferon has been reported to be effective, but data from phase III randomized trials is not yet available.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



<sup>b</sup>See Principles of Surgical Management (BL-A).

<sup>c</sup>The modifier “c” refers to clinical staging based on bimanual examination under anesthesia and endoscopic surgery (biopsy or transurethral resection) and imaging studies. The modifier “p” refers to pathologic staging based on cystectomy and lymph node dissection.


<sup>j</sup>There are data to support equivalent survival rates, but not uniform consensus about the role of these approaches. Not all institutions have experience with these multidisciplinary treatment approaches which require a dedicated team.

<sup>k</sup>See Principles of Chemotherapy Management (BL-D).

<sup>l</sup>See Principles of Radiation Management of Invasive Disease (BL-E).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



<sup>b</sup>See Principles of Surgical Management (BL-A).

<sup>c</sup>The modifier “c” refers to clinical staging based on bimanual examination under anesthesia and endoscopic surgery (biopsy or transurethral resection) and imaging studies. The modifier “p” refers to pathologic staging based on cystectomy and lymph node dissection.

<sup>k</sup>See Principles of Chemotherapy Management (BL-D).

<sup>l</sup>See Principles of Radiation Management of Invasive Disease (BL-E).


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## CLINICAL STAGING

## PRIMARY TREATMENT

## ADJUVANT TREATMENT



<sup>b</sup>See Principles of Surgical Management (BL-A).


<sup>k</sup>See Principles of Chemotherapy Management (BL-D).

<sup>l</sup>See Principles of Radiation Management of Invasive Disease (BL-E).

<sup>m</sup>If technically possible.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



<sup>b</sup>See Principles of Surgical Management (BL-A).

<sup>k</sup>See Principles of Chemotherapy Management (BL-D).

<sup>l</sup>See Principles of Radiation Management of Invasive Disease (BL-E).

<sup>n</sup>Depending on risk of recurrence.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## PRINCIPLES OF SURGICAL MANAGEMENT

**TURBT: Papillary**

- Adequate resection with muscle if papillary high-grade lesion
- Reresection if incomplete initial resection, no muscle in specimen or large lesion

**TURBT: Tis**

- Multiple random biopsies
- Biopsy adjacent to tumor
- Prostate urethral biopsies

**TURBT: Invasive****Repeat biopsy:**

- T1, G3
- If no muscle in biopsy
- Small fragment of T2 insufficient to attribute risk
- Repeat TURBT should be considered if first TURBT does not allow adequate staging or attribution of risk factor for treatment selection or when using bladder-preserving treatment by chemotherapy and/or RT

**RADICAL CYSTECTOMY**

- Radical cystectomy should include bilateral extended or regional node dissection

**SEGMENTAL CYSTECTOMY**

Solitary lesion in location amenable to segmental resection with adequate margin, no CIS. Pelvic lymphadenectomy should be performed in conjunction with the segmental cystectomy

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## PROBABILITY OF RECURRENCE AND PROGRESSION

<u>Pathology</u>	<u>Probability of Recurrence</u>	<u>Probability of Progression to Muscle Invasion</u>
Ta, G1	50%	Minimal
Ta, G2	50%	Low
Ta, G3	60%	Moderate
T1, G2	50%	Moderate
T1, G3	70%	High
CIS	50%–90%	High

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## NON-UROTHELIAL CELL CARCINOMA (UCC) OF THE BLADDER

Same as UCC management with the following issues:

**Mixed Histology:**

- [Follow Urothelial Carcinoma of the Bladder \(BL-1\)](#) with complete response less likely if bladder sparing considered

**Pure Squamous:**

- Cystectomy or RT

**Adenocarcinoma:**

- MVAC ineffective
- Cystectomy or partial cystectomy
- Consider 5-FU-based therapy
- Potential urachal tumors require complete urachal resection

**Small-cell:**

- Neoadjuvant or adjuvant chemotherapy using small-cell regimens and local treatment (surgery, radiotherapy)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## PRINCIPLES OF CHEMOTHERAPY MANAGEMENT

**First-line chemotherapy:**

- Toxicities with MVAC limit its use, however it is the historical standard of care based on improved survival and response rates when compared to older regimens.
- Gemcitabine and cisplatin. A large randomized trial comparing this regimen to MVAC demonstrated that gemcitabine/cisplatin was not inferior to MVAC in terms of survival, but did demonstrate a more favorable toxicity profile. This combination is considered a standard first-line choice for most patients.

**Alternative Regimens**

These newer regimens demonstrate activity in bladder cancer, but have not been compared to reference regimens above:

- Cisplatin/paclitaxel
- Gemcitabine/paclitaxel
- Gemcitabine/docetaxel
- Cisplatin/gemcitabine/paclitaxel or docetaxel

**Combination regimens:**

- Considered for patients with locally advanced disease or limited metastatic recurrence where consolidation surgery may be an option.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## PRINCIPLES OF RADIATION THERAPY MANAGEMENT OF INVASIVE DISEASE

- External beam radiation is rarely appropriate for patients with recurrent Ta-T1 tumors or diffuse CIS.
- Precede radiation by maximal TUR of the tumor when safely possible.
- Combining concurrent chemotherapy with radiation is encouraged for added tumor cytotoxicity. Such therapy is optimally given by dedicated multidisciplinary teams.
- Simulate and treat patients with the bladder empty.
- Use multiple fields from high-energy linear accelerator beams.
- Treat the whole bladder with or without pelvic lymph nodes with 40-55 Gy and then boost the bladder tumor to a total dose of 64-66 Gy excluding, if possible, normal areas of the bladder from the high-dose volume.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## PRINCIPLES OF PATHOLOGY MANAGEMENT

**Malignancy Grading of Bladder Carcinoma: Old and New Systems\***

<b>Modified Bergkvist 1987</b>	<b>WHO 1973</b>	<b>WHO/ISUP 1998 Consensus WHO, 2004</b>
<b>Papilloma grade 0</b>	<b>Papilloma</b>	<b>Papilloma</b>
<b>Papilloma with atypia grade 1 potential</b>	<b>TCC grade 1</b>	<b>Papillary urothelial neoplasm of low malignant potential</b>
<b>Urothelial carcinoma grade 2A</b>	<b>TCC grade 1</b>	<b>Urothelial carcinoma low grade</b>
<b>Urothelial carcinoma grade 2B</b>	<b>TCC grade 2</b>	<b>Urothelial carcinoma high grade</b>
<b>Urothelial carcinoma grade 3</b>	<b>TCC grade 3</b>	<b>Urothelial carcinoma high grade</b>

*\*From Droller MJ: Bladder Cancer, Current Diagnosis and Treatment. Totowa, NJ, 2001.*

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## WORKUP

- Renal pelvis →
- IVP/CT urogram
  - Cytology
  - Cystoscopy
  - Retrograde pyelogram ± Ureteroscopy ± CT
  - Renal function tests
    - Renal scan (optional)
  - Chest x-ray
  - CBC, chemistry profile
  - Bone scan if abnormal enzymes or bone signs or symptoms

Operable

Low grade

High grade, large, or parenchymal invasion

Metastatic

## PRIMARY TREATMENT

Nephroureterectomy with cuff of bladder  
or  
Nephron-sparing procedure  
or  
Endoscopic resection ± postsurgical intrapelvic chemotherapy or BCG

Nephroureterectomy with cuff of bladder + regional lymphadenectomy

Chemotherapy<sup>a</sup>


[See Adjuvant Treatment and Follow-up \(UTT-3\)](#)

<sup>a</sup>[See Principles of Chemotherapy Management \(BL-D\)](#).

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## WORKUP

## PRIMARY TREATMENT



**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**PATHOLOGIC STAGING**

**ADJUVANT TREATMENT<sup>b</sup>**

**FOLLOW-UP**

Primary Treatment  
Renal Pelvis  
and TCC Ureter

pT0, pT1

None

- Cystoscopy every 3 mo for 1 y, then at increasing intervals
- Upper tract imaging 1-2 y intervals<sup>c</sup>
- Ureteroscopy 3-12 mo intervals if endoscopic resection
- ± CT scan or MRI
- ± Chest x-ray

pT2, pT3,  
pT4, pN+

Consider adjuvant  
chemotherapy

- Cystoscopy every 3 mo for 1 y, then at increasing intervals
- Upper tract imaging 1-2 y intervals<sup>c</sup>
- ± CT scan or MRI
- ± Chest x-ray

<sup>b</sup>Follow recommendations for adjuvant chemotherapy after ensuring that patient is fully staged to rule out metastatic disease.

<sup>c</sup>Imaging may include IVP, CT urography (if available), retrograde pyelogram or MRI urogram.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

WORKUP

PATHOLOGY

ADDITIONAL  
WORKUP

PRIMARY TREATMENT



<sup>a</sup>Imaging may include IVP, CT urography, renal ultrasound with retrograde pyelogram, or MRI urogram.

<sup>b</sup>[See Principles of Chemotherapy Management \(BL-D\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

## Staging

**Table 1**  
**American Joint Committee on Cancer (AJCC)**  
**TNM Staging System For Bladder Cancer**

### Primary Tumor (T)

- TX** Primary tumor cannot be assessed
- T0** No evidence of primary tumor
- Ta** Noninvasive papillary carcinoma
- Tis** Carcinoma *in situ*: “flat tumor”
- T1** Tumor invades subepithelial connective tissue
- T2** Tumor invades muscle
  - T2a** Tumor invades superficial muscle (inner half)
  - T2b** Tumor invades deep muscle (outer half)
- T3** Tumor invades perivesical tissue
  - T3a** Microscopically
  - T3b** Macroscopically (extravesical mass)
- T4** Tumor invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall
  - T4a** Tumor invades prostate, uterus, vagina
  - T4b** Tumor invades pelvic wall, abdominal wall

### Clinical Staging

Primary tumor assessment includes bimanual examination under anesthesia before and after endoscopic surgery (biopsy or transurethral resection) and histologic verification of the presence or absence of tumor when indicated. Bimanual examination following endoscopic surgery is an indicator of clinical stage. The finding of bladder wall thickening, a mobile mass, or a fixed mass suggests the presence of T3a, T3b, and T4b disease, respectively. Appropriate imaging techniques for lymph node evaluation should be used. When indicated, evaluation for distant metastases includes imaging of the chest, biochemical studies, and isotopic studies to detect common metastatic sites.

### Pathologic Staging

Microscopic examination and confirmation of extent are required. Total cystectomy and lymph node dissection generally are required for this staging. Laterality does not affect the N classification.

### Regional Lymph Nodes (N)

Regional lymph nodes are those within the true pelvis; all others are distant lymph nodes.

- NX** Regional lymph nodes cannot be assessed
- N0** No regional lymph node metastasis
- N1** Metastasis in a single lymph node, 2 cm or less in greatest dimension
- N2** Metastasis in a single lymph node, more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, none more than 5 cm in greatest dimension
- N3** Metastasis in a lymph node more than 5 cm in greatest dimension

### Distant Metastasis (M)

- MX** Distant metastasis cannot be assessed
- M0** No distant metastasis
- M1** Distant metastasis

### Stage Grouping

<b>Stage 0a</b>	Ta	N0	M0
<b>Stage 0is</b>	Tis	N0	M0
<b>Stage I</b>	T1	N0	M0
<b>Stage II</b>	T2a	N0	M0
	T2b	N0	M0
<b>Stage III</b>	T3a	N0	M0
	T3b	N0	M0
	T4a	N0	M0
<b>Stage IV</b>	T4b	N0	M0
	Any T	N1	M0
	Any T	N2	M0
	Any T	N3	M0
	Any T	Any N	M1

### Histopathologic Type

The histologic types are the following:  
**Urothelial (transitional cell) carcinoma**  
**In situ**  
Papillary  
Flat  
With squamous metaplasia  
With glandular metaplasia  
With squamous and glandular metaplasia

### Squamous cell carcinoma

### Adenocarcinoma

### Undifferentiated carcinoma

The predominant cancer is urothelial (transitional cell) carcinoma.

### Histopathologic Grade (G)

- GX** Grade cannot be assessed
- G1** Well differentiated
- G2** Moderately differentiated
- G3-4** Poorly differentiated or undifferentiated

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York. (For more information, visit [www.cancerstaging.net](http://www.cancerstaging.net).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer-Verlag New York, Inc., on behalf of the AJCC.

## Manuscript

### NCCN Categories of Consensus

**Category 1:** There is uniform NCCN consensus, based on high-level evidence, that the recommendation is appropriate.

**Category 2A:** There is uniform NCCN consensus, based on lower-level evidence including clinical experience, that the recommendation is appropriate.

**Category 2B:** There is nonuniform NCCN consensus (but no major disagreement), based on lower-level evidence including clinical experience, that the recommendation is appropriate.

**Category 3:** There is major NCCN disagreement that the recommendation is appropriate.

**All recommendations are category 2A unless otherwise noted.**

### Overview

An estimated 61,420 new cases of urinary bladder cancer will be diagnosed in the United States (44,690 men and 16,730 women) in 2006, making the disease the fourth most common cancer in men and the ninth most common neoplasm in women.<sup>1</sup> During that same period, approximately 13,060 deaths (8990 men and 4070 women) from bladder cancer are anticipated.<sup>1</sup> Bladder cancers are rarely diagnosed in individuals younger than 40 years. Because the median age of diagnosis is 65 years, medical comorbidities are a frequent consideration in patient management.

The clinical spectrum of bladder cancer can be divided into 3 categories that differ in prognosis, management, and therapeutic

aims. The first category consists of noninvasive tumors, for which treatment is directed at reducing recurrences and preventing progression to a more advanced stage. The second group encompasses the invasive lesions, and the goal of therapy is to determine if the bladder should be removed or preserved without compromising survival, and to determine if the primary lesion can be managed independently or if patients are at high risk for distant spread requiring systemic approaches to improve the likelihood of cure. The critical concern of therapy for the third group, consisting of metastatic lesions, is how to prolong life. Numerous agents with different mechanisms of action have antitumor effects in this disease. The issue has become how to use these agents to achieve the best possible outcome.

### Histology

More than 90% of urothelial tumors originate in the urinary bladder, 8% originate in the renal pelvis, and the remaining 2% originate in the ureter and urethra. Urothelial (transitional cell) carcinomas, the most common histologic subtype in the United States, may develop anywhere transitional epithelium is present, from the renal pelvis to the ureter, bladder, and proximal two thirds of the urethra. The distal third of the urethra is dominated by squamous epithelium. The diagnosis of squamous cell tumors, which constitute 3% of the urinary tumors diagnosed in the United States, requires the presence of keratinization in the pathologic specimen. In areas where infections with *Schistosoma haematobium* are endemic (such as Egypt), 40% of urothelial tumors are pure squamous cell carcinomas.<sup>2</sup>

Of the other histologic subtypes, 2% are adenocarcinomas and 1% are small-cell tumors (with or without an associated paraneoplastic syndrome). Adenocarcinomas often occur in the dome of the bladder in the embryonal remnant of the urachus,<sup>3,4</sup> in the periurethral tissues, or with a signet-ring–cell histology. Urothelial tumors often have a mixture of histologic subtypes, such as urothelial (transitional cell) and squamous or urothelial (transitional cell) and adenocarcinoma. These should be treated as urothelial carcinomas.<sup>5</sup>

The systemic chemotherapy regimens used to treat urothelial carcinomas (transitional cell tumors) are generally ineffective for tumors with a pure nonurothelial (nontransitional cell) histology, such as adenocarcinoma or squamous carcinoma. In some cases with a mixed histology, only the nonurothelial (nontransitional cell) component remains after systemic treatment.

### Clinical Presentation and Workup

The most common presenting symptom in patients with bladder cancer is microscopic hematuria, although urinary frequency from irritation or a reduced bladder capacity can also develop. Less commonly, a urinary tract infection is the presenting symptom, or upper tract obstruction or pain may occur for a more advanced lesion. Patients presenting with these symptoms should be evaluated with office cystoscopy to determine if a lesion is present. If one is documented, the patient should be scheduled for a transurethral resection of the bladder tumor (TURBT) to confirm the diagnosis and determine the extent of disease within the bladder.

If the cystoscopic appearance of the tumor is solid (sessile), high-grade, or suggests invasion into muscle, a computed tomographic (CT) scan of the abdomen and pelvis is recommended before the TURBT. Because the results of a CT scan rarely alter the management of tumors with a purely papillary appearance or cases in which only the mucosa appears abnormal, suggesting carcinoma in situ (CIS), a CT scan is not recommended in these situations. Additional workup for all patients should include evaluation of the upper tracts with an intravenous pyelogram (IVP), retrograde pyelogram, and urine cytology.

TURBT with a bimanual examination under anesthesia (EUA) is performed to resect visible tumor and to sample muscle within the area of the tumor to assess whether invasion has occurred. When a large papillary lesion is noted, more than one session may be needed to completely resect the tumor. With CIS, biopsy of sites adjacent to the tumor and multiple random biopsies may be performed to assess for a field change. A transurethral resection biopsy of the prostate may also be considered. Finally, if an invasive tumor is noted, an adequate sample of muscle must be obtained. A small fragment of tumor with few muscle fibers is inadequate for assessing the depth of invasion and guiding treatment recommendations.

Additional diagnostic tests, such as a bone scan, should be performed if clinically indicated. Treatment decisions are then based on disease extent within the 3 general categories: noninvasive, invasive, or metastatic.

In the presence of a positive cytology and a normal cystoscopy, the upper tracts (and the prostate in men) must be evaluated.

Management of bladder cancer is based on the pathologic findings of the biopsy specimen, with attention to histology, grade, and depth of invasion. These factors are used to estimate the probability of recurrence and progression to a more advanced stage. Because the clinical benefit of ploidy, vascularity, p53 status, and other markers (e.g., NMP-22, BTA, M344) is uncertain, they are not used to guide treatment decisions outside of the experimental protocol setting.

### Pathology and Natural History

Approximately 70% of newly detected cases are exophytic papillary tumors confined largely to the mucosa (Ta) (70%) or, less often, to the submucosa (T1) (30%).<sup>6</sup> These tumors tend to be friable and have a high propensity for bleeding. Their natural history is characterized by a tendency to recur in the same portion or another part of the bladder over time (a phenomenon termed *polychronotropism*), and these recurrences can be either at the same stage as the initial tumor or at a more advanced stage.

Papillary tumors confined to the mucosa or submucosa are generally managed endoscopically with complete resection. Progression to a more advanced stage may result in local symptoms or, less commonly, symptoms related to metastatic disease.

An estimated 10% to 70% of patients with a tumor confined to the mucosa will experience a recurrence or new occurrence of urothelial (transitional cell) carcinoma within 5 years. These probabilities of

progression vary as a function of the initial stage and grade. Refining these estimates for individual patients is an area of active research.<sup>7</sup>

### Staging and Grading

The most commonly used staging system is the tumor, node, metastasis (TNM) system,<sup>8</sup> as shown in [Table 1](#).

Bladder carcinomas are graded and differentiated (G1), moderately differentiated (G2), or poorly differentiated or undifferentiated (G3–4). However, determining grade has a greater impact on the management of noninvasive tumors because most muscle-invasive tumors (i.e., > T1) are G3. An alternative grading system of low or high grade has been proposed,<sup>9,10</sup> and researchers expect to transition to this classification system over the next 3 years. The present classification system will be retained for now because it is commonly used by practicing urologists. The different classification systems are compared in the “Principles of Pathology Management” on page [BL-F](#).

Papillomas are considered benign tumors that closely resemble the normal urothelium. In contrast, grade 1 papillary carcinomas can be recognized histologically because they have more than the normal 7 epithelial layers, normal polarity of the nuclei, and minimal pleomorphism. Papillomas and Ta, G1 carcinomas are managed almost exclusively with endoscopic means because they generally do not progress to a higher, more lethal stage. In contrast, Ta, G3 tumors have a much higher chance of progression to a more advanced stage. After stage and grade have been determined, treatment decisions are based on the depth of invasion and extent of disease.

## Treatment

The disciplines of urologic surgical, radiation, and medical oncology are required for treating bladder cancer. For many of the complex strategies, the involvement of multidisciplinary teams optimizes results. The general principles for surgery, chemotherapy, and radiation therapy are explained on [BL-A](#), [BL-D](#), and [BL-E](#), respectively.

### Treatment of Non–Muscle-Invasive Disease

Non–muscle-invasive tumors are divided into noninvasive papillomas or carcinomas (Ta), those invading the lamina propria (T1), and CIS.<sup>11</sup> These tumors have previously been referred to as *superficial*, which is an imprecise term that should be avoided. In some cases, a papillary or T1 lesion will be documented as having an associated in situ component (Tis). Standard treatment in these cases is repeat transurethral resection. However, depending on the depth of invasion and grade, intravesical therapy may be recommended. This suggestion is based on the estimated probability of recurrence (i.e., new tumor formation within the bladder) and progression to a more advanced, usually invasive stage, which are events that should be considered independently. Cystectomy is rarely considered for a Ta, G1, or G2 lesion.

Intravesical therapy is used in 2 general settings: as prophylactic or adjuvant therapy after a complete endoscopic resection or, rarely, as therapy with the goal of eradicating residual disease that could not be completely resected. This distinction is important, because most published data reflect prophylactic or adjuvant use with the goal of preventing recurrence or delaying progression to a higher grade or

stage. In many cases, intravesical therapy is given to patients who do not require it because the probability of recurrence or progression is low. Management of the different histologic subtypes of different grades is outlined in subsequent sections.

#### **Papilloma/Ta, G1, or G2:**

Transurethral resection without intravesical therapy is the standard treatment for Ta, G1 and Ta, G2 tumors. Because patients diagnosed with these tumors have a relatively high risk for recurrence, the panel recommends that, in addition to observation, experts consider administering a single dose of intravesicular chemotherapy (not immunotherapy) within 24 hours of resection. Close follow-up is needed, although the risk for progression to a more advanced stage is low. As a result, these patients are advised to undergo a cystoscopy at 3 months initially, and then at increasing intervals. If no recurrences develop during the first year, the interval between evaluations can be increased. Patients with a documented recurrence are treated with TURBT and adjuvant therapy based on the stage and grade of the recurrent lesion, and are then followed up at 3-month intervals. Intravesical therapy is recommended for patients with a history of recurrences.

#### **Ta, G3 Disease:**

Tumors staged as Ta, G3 lesions are considered high-grade papillary tumors with a relatively high risk for recurrence and progression towards more invasiveness. Therefore, in addition to observation, they are treated with intravesical bacillus Calmette-Guérin (BCG) or

mitomycin (MMC), in the same manner as T1, G1-2 tumors, with BCG the preferred option for postoperative treatment.

**Tis:**

Primary Tis is a high-grade lesion that is believed to be a precursor of invasive bladder cancer. Standard therapy for this lesion is a complete endoscopic resection followed by intravesical therapy with BCG. This therapy is generally given once a week for 6 weeks, followed by a rest period of 4 to 6 weeks, with a full reevaluation at week 12 (i.e., 3 months) after the start of therapy. Patients with Tis who have recurrent or persistent disease at the 12-week (3-month) evaluation can be given a second course of BCG or MMC induction therapy (no more than 2 consecutive courses). If a second course of BCG is given and residual disease is seen at the second 12-week (3-month) follow-up, a cystectomy should be strongly considered. Depending on prior treatment, extent of the disease, and frequency of recurrences, intravesical therapy with a different intravesical agent (mitomycin, or less commonly valrubicin; interferon-alpha; or BCG plus interferon-alpha) is an alternative to cystectomy. The combination of intravesical BCG and interferon alpha-2B has been shown to be effective in this setting, but data from the phase III randomized study are not currently available. In some centers, however, these patients might still be candidates for investigational therapies. For patients showing complete response at the follow-up cystoscopy, whether 1 or 2 courses of induction therapy were administered, maintenance therapy with BCG is advised, although this recommendation is not universal.

Regardless of whether maintenance therapy is administered, patients with Tis should be followed up at 3-month intervals with a urinary

cytology and cystoscopy for the first 2 years, every 6 months in the third and fourth years if no recurrences are documented, and then annually. Imaging of the upper tract collecting system every 1 to 2 years is also recommended with or without urinary tumor markers (category 2B) in selected cases. If progression to an invasive lesion is documented at any point during follow-up, a radical cystectomy is recommended. Although controversial, patients who present with recurrent superficial tumors before a muscle-invading lesion is documented are generally not considered candidates for bladder-sparing approaches.

**T1 DISEASE:**

T1 lesions, those invading lamina propria, are considered to be potentially dangerous (usually T1, G2 or T1, G3) and have a high risk for recurrence and progression. These tumors may occur as solitary lesions or as multifocal tumors with or without an associated in situ component. These are also treated with a complete endoscopic resection followed by intravesical therapy (this is optional for G1 or G2 lesions). Within the category of T1 disease, 2 risk strata can be identified: low-risk (G1, G2, or solitary) and high-risk (G3 or multifocal lesions, tumors associated with vascular invasion, or lesions that recur after BCG treatment).

**Low-Risk Disease:**

After undergoing the initial transurethral resection, patients with low-risk disease are observed or undergo intravesical treatment with BCG or MMC. Follow-up is similar to that for Ta, G1–2 disease, with a urinary cytology and cystoscopy recommended at 3-month intervals for the first 2 years, repeated at increasing intervals over the next 2 years, and annually thereafter. If cytology study is found to be positive despite the

negative imaging and cystoscopy results, random biopsies, including transurethral resection and prostate biopsy in male patients, are recommended. Recurrent disease is treated as appropriate for the stage documented at relapse.

**High-Risk Disease:**

Patients with high-risk disease (T1, G3) can be treated with a course of BCG (preferred, category 1), MMC, or radical cystectomy after a certain and satisfied resection. If the complete resection is uncertain because of the tumor size and location, no muscle is shown in the specimen, lymphovascular invasion has occurred, or inadequate staging is speculated, repeat resection of tumor or cystectomy followed by intravesical therapy with BCG (category 1) or MMC is recommended ([BL-2](#)). Evolving data suggest that early cystectomy may be preferred if residual disease is found, because of the high risk for progression to a more advanced stage.<sup>12</sup> If high-risk disease is managed conservatively and does not respond to BCG, a cystectomy should be performed.

**Treatment of Muscle-Invasive Disease**

Before any treatment is advised, several workup procedures are recommended to determine the clinical staging. Laboratory studies, such as complete blood cell count and chemistry profile, including alkaline phosphate, must be performed, and the patient should be assessed for the presence of regional or distant metastases. This evaluation should include a cystoscopy, EUA/TURBT, chest radiograph, bone scan in patients with symptoms or elevated alkaline phosphate, and evaluation of the upper tracts with a CT or magnetic resonance scan of the abdomen and pelvis. Some physicians advocate performing magnetic resonance imaging (MRI) to determine the depth

of invasion within the bladder and, in particular, to ascertain whether a tumor has reached the perivesical fat (T3b). Unfortunately, CT scans, ultrasound, and MRI cannot accurately predict the true depth of invasion.<sup>13,14</sup>

**Organ-Confined Disease (T2a, T2b):**

Surgical treatment with radical cystectomy is still the most effective local therapy in muscle-invasive bladder cancer. The critical issues in the management and prognosis of these patients are whether a palpable mass is appreciated at EUA and if the tumor has extended through the bladder wall. Tumors that are organ-confined (T2) have a better prognosis than those that have extended through the bladder wall to the perivesical fat (T3) and beyond.

Primary surgical treatment for T2 lesions include radical cystectomy with the consideration of neoadjuvant chemotherapy, and segmental cystectomy only in patients with a single tumor (solitary lesion in a suitable location) and no any presence of CIS, or previous multifocal bladder cancers. If no neoadjuvant chemotherapy was given, postoperative adjuvant chemotherapy is considered based on pathologic risk, such as positive nodes and pathologic T3 lesions. If segmental cystectomy was performed, adjuvant radiotherapy or chemotherapy based on pathologic risk, such as positive nodes, positive margin, high-grade, and pathologic T3 lesions, should be considered ([BL-4](#)).

For patients with superficial muscle-invasive T2 disease without hydronephrosis, bladder-sparing treatment (category 2B) with chemotherapy and radiation therapy may be possible after complete TURBT. In patients with extensive comorbid disease or poor

performance status, chemotherapy alone, radiation therapy, or TURBT is recommended. For those not undergoing cystectomy, evaluation with cystoscopy and tumor-site rebiopsy are necessary after primary treatment. Radical cystectomy is the standard treatment if a tumor is found. Otherwise, observation, further consolidation chemotherapy with radiation, or adjuvant chemotherapy alone is recommended.

***Surgical Approaches:***

The appropriate surgical procedure involves a cystoprostatectomy in men and, in women, a cystectomy and usually a hysterectomy, followed by the formation of a urinary diversion. Forms of urinary diversion include an ileal conduit or directing urine to an internal urinary reservoir, with drainage to the abdominal wall or the urethra. Relative contraindications to urethral drainage include CIS in the prostatic urethra or positive urethral margin. Orthotopic diversion or a neobladder provides bladder function similar to that of a native bladder with some increased risk for nighttime incontinence or urinary retention requiring intermittent self-catheterization.

***Radical Cystectomy:***

Unfortunately, the accuracy of the staging cystoscopy and biopsy is modest in making these distinctions, with understaging and overstaging encountered frequently. Consequently, most physicians advise a radical cystectomy when muscle-invasive disease is documented, and defer deciding whether to administer postoperative treatment until after the pathologic findings have been evaluated.

Follow-up after a cystectomy should include urine cytology, liver function tests, creatinine, electrolytes, chest radiograph, and imaging of the abdomen and pelvis every 3 to 6 months for 2 years and then as

clinically indicated. Patients should be monitored annually for vitamin B<sub>12</sub> deficiency if a continent diversion was created. A urethral wash cytology every 6 to 12 months is advised, particularly if CIS involved the urethra or diffuse CIS was found within the bladder. A postoperative CT scan is advised to define the revised anatomy of the pelvis and should be repeated every 3 to 6 months for 2 years if the risk for recurrence is high, and then every 12 months.

***Partial Cystectomy:***

In approximately 5% of cases or fewer, an initial invasive tumor develops in an area of the bladder where an adequate margin (minimum of 2 cm) of noninvolved urothelium can be removed along with the tumor without compromising continence or significantly reducing bladder capacity. Partial cystectomy is most frequently recommended for lesions that develop on the dome of the bladder and have no associated CIS in other areas of the urothelium. Relative contraindications to this procedure are lesions that occur in the trigone or bladder neck. The requirement for a ureteral reimplantation, however, is not an absolute contraindication.

Similar to radical cystectomy, partial cystectomy begins with a laparotomy and evaluation of the pelvic lymph nodes before the decision is made to remove the affected portion of the bladder. If the intraoperative findings preclude a partial cystectomy, a radical cystectomy is performed. The decision to recommend adjuvant radiation or chemotherapy is based on the pathologic stage (i.e., positive nodes or perivesical tissue involvement), similar to that for patients who undergo a radical cystectomy.

Follow-up after a partial cystectomy is similar to that for a radical cystectomy, with the addition of monitoring for relapse in the bladder and systemic recurrence, with serial cytologic examinations and cystoscopies at 3-month intervals. A local recurrence within the preserved bladder should be evaluated as a new cancer. Patients with a superficial recurrence (Tis, Ta, or T1) may be considered for intravesical BCG treatment. If BCG elicits no response, palliative cystectomy is a possible option. Those with an invasive recurrence should undergo cystectomy or, if they are not surgical candidates, radiotherapy (if no prior radiotherapy was given), chemotherapy, or both should be considered. Palliative TURBT is also an option ([BL-7](#)).

If a positive cytology is documented in a patient with a normal bladder, an evaluation of the upper tracts with selective washings and a prostatic urethral biopsy is recommended. Pending these findings, management is the same as that for upper tract or prostatic urethral disease, as described in subsequent sections.

**Neoadjuvant Chemotherapy:**

Increasing data support the role of neoadjuvant chemotherapy before cystectomy for T2 and T3 lesions. Two randomized trials show a survival benefit, particularly in patients with clinical T3 disease (palpable mass at EUA or unequivocal mass on CT). After 3 cycles of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), the United States study showed no apparent increase in postoperative morbidity or mortality.<sup>15–17</sup>

**Adjuvant Chemotherapy:**

Data conflict regarding the role of adjuvant systemic chemotherapy in invasive bladder cancer because no randomized comparisons of

adequate sample size have definitively shown a survival benefit of such therapy.<sup>18</sup> Many trials showing a survival benefit were not randomized, raising the question of selection bias in the analysis of outcomes.

Two trials, one from the University of California and the other from Germany, showed a survival advantage from therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) in the California study and with MVAC or methotrexate, vinblastine, epirubicin, and cisplatin (MVEC) in the German trial. However, methodologic issues have raised questions as to the applicability of these studies to all patients with urothelial tumors. In the German trial, patients who experienced relapse in the control arm did not undergo chemotherapy, which is not typical of more contemporary series.

Nevertheless, the results of currently available trials show that adjuvant chemotherapy can delay recurrences, which, for most patients, is beneficial enough to justify the routine administration of chemotherapy in those at a high risk for relapse. A minimum of 4 cycles of a cisplatin-based combination, such as MVAC, should be used in patients undergoing adjuvant therapy. No data support the use of adjuvant chemotherapy for nonurothelial (nontransitional cell) carcinomas, regardless of stage.

Patients with tumors that are pathologic stage T2 or less and have no nodal involvement are considered to have lower risk and do not necessarily require adjuvant chemotherapy. These patients should be monitored with urinary cytology. T2 tumors with nodal involvement or other high-risk pathologic features, such as high-grade histology, transmural invasion, or vascular invasion, should be considered for

adjuvant chemotherapy or, less commonly, radiotherapy. Some groups are beginning to stratify patients based on the p53 status of the tumor, because tumors with more than 20% of positive cells seem to have a higher risk for systemic relapse. Determining the p53 status of the tumor is still considered an experimental procedure and is not part of routine management.

Annual CT scan at baseline is advised because of higher risk for relapse. If relapse is documented, palliative chemotherapy is recommended using a regimen to which the patient was not previously exposed.

***Bladder-Sparing Options:***

Within the categories of T2 and T3a urothelial (transitional cell) carcinomas, selected patients may be considered for bladder-sparing approaches (category 2B for T2 disease). Options include aggressive endoscopic transurethral resection alone, transurethral resection followed by chemotherapy alone, radiotherapy alone, or a combination of chemotherapy and radiotherapy. No uniform consensus was reached about the applicability of these approaches to the management of T2 tumors.

Bladder-preserving approaches are reasonable alternatives to cystectomy for patients who are medically unfit for surgery and those seeking an alternative. The decision to use a bladder-sparing approach is partially based on the location of the lesion, depth of invasion, size of the tumor, status of the “uninvolved” urothelium, and status of the patient (e.g., bladder capacity, bladder function, comorbidities). An antecedent history of superficial disease should also be considered. Those with hydronephrosis are poor candidates for bladder-sparing

procedures. Metastatic disease must be excluded. Patients for whom a bladder-sparing approach is considered should undergo a complete transurethral resection of the tumor as safely as possible, examination under anesthesia, and metastatic workup before therapy is initiated.

With any of the alternatives to cystectomy, a concern exists over the ability to determine with certainty which bladders that appear to be endoscopically free of tumor (T0) based on a clinical assessment that includes a repeat TURBT, are in fact pathologically free of tumor (pT0). Depending on the series, upward of 30% to 40% of bladders believed to be free of disease preoperatively after chemotherapy were found to have residual disease at cystectomy.<sup>19</sup> The frequency of residual disease is lower for patients who present with T2 disease but, nevertheless, must be considered when proposing a bladder-sparing approach. When possible, bladder-sparing options should be chosen in the context of clinical trials. The guidelines indicate that after maximal transurethral resection, observation, chemotherapy alone, radiotherapy alone, or chemotherapy combined with radiotherapy are appropriate treatment options. These approaches have been shown to be beneficial in selected cases. However, only chemotherapy combined with radiotherapy has been formally evaluated in prospective randomized comparisons; the others are still considered investigational.

All bladder-sparing approaches are based on the principle that not all cases require an immediate cystectomy and that the decision to remove the bladder can be deferred until the response to therapy is assessed. When chemotherapy combined with radiotherapy is used, a cystoscopy with bladder biopsy is performed midway through treatment (induction phase). If disease is seen, cystectomy is recommended. For

all of the other methods, repeat transurethral resection is performed 2 to 3 months after induction therapy. If persistent disease is observed, palliative cystectomy is recommended when possible.

Routine follow-up to rule out recurrence after completion of therapy involves cystoscopy with or without biopsy every 3 months within the first year, then at increased intervals thereafter. Attention to the bladder as a site of recurrence is only one part of the overall management of patients undergoing bladder preservation, because these individuals remain at risk for recurrence elsewhere in the urothelial tract and distantly. Imaging studies should also be performed as outlined under postcystectomy follow-up. Continued monitoring of the urothelium, with urinary cytologies at 3-month intervals, is a routine part of the management of all cases in which the bladder is preserved. The follow-up frequency is influenced by the treatment approach; patients undergoing observation or chemotherapy without radiotherapy should be followed up more frequently than those undergoing radiation.

***Transurethral Resection Alone:***

Transurethral resection alone may be curative in selected cases in which the lesion is solitary, less than 2 cm in size, and has minimally invaded the muscle. These cases should also have no associated in situ component, palpable mass, or associated hydronephrosis.<sup>20</sup>

If considered for TURBT alone, patients should undergo an aggressive re-resection of the site within 4 weeks of the primary procedure to ensure that no residual disease is present. If the repeat TURBT is negative for residual tumor, the patient can be managed conservatively with repeat endoscopic evaluations and cytologies every 3 months until

a relapse is documented. At that point, management would depend on the stage of the lesion documented at relapse.

***Radiotherapy Alone:***

Radiation alone is not considered standard treatment for patients with an invasive bladder tumor. Because the initial complete response and long-term bladder preservation rates are higher with chemotherapy combined with radiotherapy, this is the preferred treatment. Because the results of radiotherapy alone are considered inferior to those of radical surgery, radiotherapy is only indicated for those who cannot tolerate a cystectomy or chemotherapy because of medical comorbidities.

***Chemotherapy Alone:***

The use of chemotherapy alone is not considered adequate without additional treatment to the bladder and remains investigational. This view is based on reported series showing that the complete pathologic response proportions in the bladder using neoadjuvant chemotherapy alone were only 20% to 30%. A higher proportion of bladders can be rendered tumor-free and therefore preserved when chemotherapy is followed by a partial cystectomy or when chemotherapy is combined with concurrent radiotherapy.

When chemotherapy alone is used, 2 to 3 cycles of therapy are generally administered, and a reassessment that includes a cystoscopy and biopsy is advised. This evaluation is performed to exclude progression or a negative response, which would warrant an immediate cystectomy.

Patients who respond to 2 to 3 cycles of chemotherapy are often advised to complete an additional 1 to 4 cycles followed by a cystoscopy and biopsy. At that point, management of the bladder is determined. In general, if residual disease is documented after 4 cycles of chemotherapy, a cystectomy should be performed. Even when no disease is documented (T0), the possibility of occult residual disease in the bladder must be factored into the therapeutic recommendations.

#### **Combined Modality Strategies**

These approaches use induction therapy with deferred management of the bladder pending the assessment of response in the primary tumor.

#### **Chemotherapy Followed by Partial Cystectomy:**

Only 5% of invasive tumors present initially in a location that is amenable to curative resection with partial cystectomy.<sup>21</sup> In one series, 27% of tumors that were originally believed to require radical cystectomy for control could be removed with partial cystectomy after MVAC chemotherapy. This approach is not widely used. This procedure has the advantages of surgically removing the diseased portion of the bladder and allowing for definitive lymph node staging. Follow-up is the same as partial cystectomy.

#### **Chemotherapy and Radiotherapy:**

Several groups have investigated the combination of concurrent or sequential chemotherapy and radiotherapy after TURBT. First, an endoscopic resection that is as complete as possible is performed. The 2 main approaches that have been examined are 1) concurrent chemotherapy with radiotherapy, and 2) neoadjuvant and concurrent chemotherapy with radiotherapy. Radiation Therapy Oncology Group protocol 89-03 compared 2 cycles of neoadjuvant MCV (methotrexate,

cisplatin, vinblastine) induction chemotherapy, followed by concurrent cisplatin and radiotherapy, with concurrent cisplatin and radiotherapy alone.<sup>17</sup> No difference in complete clinical response and 5-year overall survival was observed between the treatment arms. Unless patients are enrolled on a protocol, neoadjuvant chemotherapy before concurrent chemotherapy with radiotherapy is not recommended.

Concurrent cisplatin plus radiotherapy is the most common and well-studied chemoradiation method used to treat muscle-invasive bladder cancer. After a complete TURBT, 40 Gy of external beam radiotherapy is administered, typically with a 4-field technique. Two doses of concurrent cisplatin are given on weeks 1 and 4. After this induction phase, an endoscopic reevaluation is performed. If residual disease is noted, a cystectomy is advised. If no disease is visible and the cytology and biopsy are negative (T0), an additional 25 Gy of external-beam radiotherapy is administered along with one additional dose of cisplatin. The patient is then followed up with serial urine cytologies and cystoscopies as outlined previously.

In prospective, single-, and multi-institution series, upward of 70% of patients who completed this regimen were rendered tumor-free in the bladder at the initial post-treatment cystoscopy examination.<sup>22,23</sup> However, during follow-up, approximately one fourth of these individuals developed a new superficial or invasive lesion requiring additional therapy. These patients must also be monitored for possible systemic relapses, as described previously.

An older experience using 5-fluorouracil (5-FU) with radiotherapy showed activity for this combination.<sup>24-26</sup> More recently, the concomitant

use of cisplatin, 5-FU, and radiotherapy has been studied and the results have improved.<sup>27–29</sup> Also incorporated in some of these trials is the use of twice-daily irradiation. Initial complete response rates have been more than 85%. Although the results are promising, whether these regimens are better than the simpler concurrent cisplatin plus radiotherapy approach described above is unclear. Including patients in clinical trials using these newer approaches is of paramount importance.

***Relapses in the Bladder After Bladder-Sparing Approaches:***

Relapses are treated based on the extent of disease at relapse, with consideration of prior treatment.

Tis, Ta, or T1 tumors are generally managed with intravesical BCG therapy. If no response is noted, a cystectomy is advised. A positive cytology with no evidence of disease in the bladder should prompt selective washings of the upper tracts and an evaluation of the prostatic urethra. If the selective cytologies are positive, patients are managed as described later. Invasive disease is generally managed with radical cystectomy, and a second attempt at bladder preservation is not advisable.

All patients who experience relapse after bladder-sparing therapy and are being considered for radical cystectomy should be evaluated for medical comorbidities and undergo a full restaging evaluation to ensure that they have not developed metastatic disease. Similar to primary cystectomy, an exploratory laparotomy is performed first to ensure that the lymph nodes, omentum, or other organ sites are not involved. Even in patients with no extravesical spread, the morbidity of radical

cystectomy can be significant, although the operative mortality is low (1%–3%).

Although palliative cystectomy is the preferred approach, it may not be possible in a patient who has undergone a full course (> 65 Gy) of external-beam radiotherapy and has bulky residual disease. For these patients, palliative chemotherapy is advised, generally with a regimen that is non-cross-resistant to the one previously received. Those treated with single-agent cisplatin can be considered for a standard 3- or 4-drug regimen, whereas those who have already received a 3-drug (e.g., MCV) or 4-drug (e.g., MVAC) regimen may be considered for therapy with paclitaxel, gemcitabine, or ifosfamide, as outlined later. If the patient has not undergone radiotherapy, a course of radiotherapy should be considered.

Metastatic disease is managed with palliative chemotherapy using a regimen to which the patient has not been previously exposed.

**Non–Organ-Confined Disease (T3a, T3b/T4a, T4b)**

***T3a, T3b Disease***

Primary surgical treatment for a tumor that extends beyond the confines of the bladder wall and is still considered resectable, based on the mobility of the bladder, is radical cystectomy with consideration of neoadjuvant chemotherapy, as outlined previously. Except in highly selected cases (described later), bladder preservation is not an option in these patients because the proportion rendered tumor-free using chemotherapy alone is generally less than 10%. Tumors that are pathologic stage T3 or T4 with nodal involvement or vascular invasion have a high risk (> 50%) for systemic relapse and, therefore, may be

considered for treatment with adjuvant chemotherapy or radiotherapy. The follow-up schema is the same as previously outlined for high-risk patients.

Because of the high risk for systemic relapse in this group, based on historical series using surgery alone, several groups are also investigating combined modality approaches using neoadjuvant chemotherapy followed by surgery, or neoadjuvant chemotherapy and radiation followed by surgery. If possible, these patients should be placed in clinical trials.

Bladder preservation can be considered in selected cases in which no palpable mass on EUA and no hydronephrosis are noted. This approach should also be used in the context of an investigational protocol or considered for patients who are deemed unsuitable for surgery based on medical comorbidities. Evaluation with cystoscopy, biopsy, or cytology study is necessary after the bladder preservation treatment. If resectable tumor is found, surgical approach with cystectomy is considered. Patients with unresectable tumors undergo palliative therapy. If no tumor is detected, observation, consolidation with chemotherapy and concurrent radiotherapy, or adjuvant chemotherapy is recommended.

The general approach to this bladder-sparing strategy for these patients is similar to that outlined previously in patients with organ-confined disease. Patients are treated with a course of induction therapy (e.g., radiotherapy with concurrent chemotherapy, neoadjuvant chemotherapy alone or with radiotherapy with or without concurrent

chemotherapy) with a deferred decision on management of the primary lesion.

In patients with extensive comorbid disease or poor performance status, chemotherapy alone, radiotherapy, or TURBT is recommended. For patients not undergoing cystectomy, evaluation with cystoscopy and tumor site re-biopsy are necessary after primary treatment. Radical cystectomy is the standard treatment if tumor is found. Otherwise, observation and/or further consolidation chemotherapy with radiation and adjuvant chemotherapy or adjuvant chemotherapy alone are recommended.

#### ***T4a, T4b Disease***

Patients with unresectable disease, defined as a fixed bladder mass, or those with positive nodes before laparotomy are considered for chemotherapy alone or chemotherapy with radiotherapy. An initial stratification is based on the results of transaxial imaging. For patients who show no nodal disease on CT scans, the treatment recommendation includes 2 to 3 courses of chemotherapy with or without radiotherapy followed by cystoscopy and CT scan. If the tumor responds, options include surgery or consolidation chemotherapy with or without radiotherapy. If no response is noted, chemotherapy with radiotherapy or a new chemotherapy regimen can be used. In highly selected T4a node-negative patients, surgery with or without chemotherapy is another treatment option.

If pelvic lymph nodes larger than 2 cm are documented on imaging, a biopsy is advised to exclude nodal spread. Baseline renal function, the presence or absence of cardiac disease, and overall performance status must also be considered when making a treatment

recommendation. Patients with a good performance status and no significant comorbid disease may be considered for chemotherapy with or without radiotherapy if the nodes are positive. If they experience complete response, patients may undergo observation, receive a boost with radiotherapy, or even be considered for surgery.

Chemotherapy options are discussed under “Metastatic Disease,” whereas combined modality approaches using chemotherapy and radiotherapy are discussed previously. For patients who cannot tolerate multidrug combinations with radiotherapy, an alternative is to use radiotherapy with a radiation sensitizer, such as cisplatin administered starting on day 1 and day 21 or 5-FU with various schedules. Patients are initially treated with 45 Gy of radiation to the pelvis and bladder, with a boost of approximately 20 Gy to sites of disease within the bladder.

In highly selected patients with metastatic disease who experience a complete systemic response to chemotherapy, palliative surgery may be performed to render the patient disease-free. Data from several groups show that this aggressive approach can result in long-term survival.

Before exploratory surgery, metastatic disease must be excluded with appropriate imaging studies. If the exploration is negative for metastases within the abdomen, palliative surgery can be performed. Patients who have residual invasive disease in the bladder or nodal spread after combined modality therapy have a high risk for local and systemic relapse and should be followed up as outlined previously. If no response is noted, a change in chemotherapy is recommended or,

depending on the patient’s symptoms from the primary lesion, palliative radiotherapy may be considered.

#### ***Metastatic Disease***

Patients who present with unresectable or metastatic disease or who subsequently develop metastatic disease are generally treated with systemic chemotherapy ([Table 2](#)) or radiotherapy. These patients should undergo a staging evaluation that includes a chest radiograph, transaxial imaging of the abdomen and pelvis, and determination of creatinine clearance.

The specific chemotherapy regimen recommended partially depends on the presence or absence of medical comorbidities, such as cardiac disease and renal dysfunction, along with the risk classification of the patient based on disease extent. In general, long-term survival with combination chemotherapy alone has been reported only in good-risk patients, defined as those with good performance status, no visceral (liver, lung) or bone disease, and normal alkaline phosphatase or lactic dehydrogenase levels. Poor-risk patients, defined as those with poor performance status or visceral disease, have consistently shown very poor tolerance to multiagent combination programs and few complete remissions, which are prerequisites for cure.

Currently 3 drug types are active in the management of advanced bladder cancer: cisplatin, the taxanes, and gemcitabine. Combinations of 2 or 3 of these agents have shown clinical benefit. A commonly used combination in good-risk patients is a multidrug cisplatin-based regimen, such as MVAC<sup>30</sup> or MCV.<sup>31,32</sup> An alternative is cisplatin and gemcitabine. This recommendation is based on a direct comparison to MVAC in a large randomized trial, which showed that although

cisplatin/gemcitabine was not inferior to MVAC in terms of survival, it showed a more favorable toxicity profile.<sup>33,34</sup> This combination is considered a standard first-line choice for most patients. Some newer combination regimens, including cisplatin/paclitaxel, gemcitabine/paclitaxel, gemcitabine/docetaxel, cisplatin/gemcitabine/paclitaxel, and cisplatin/gemcitabine/docetaxel, have also shown activity in bladder cancer. They are considered for patients with locally advanced disease or limited metastatic recurrence who may be candidates for consolidation surgery.

More recently, the taxanes have been shown to be active as both front-line and palliative therapies, and both gemcitabine and ifosfamide have shown efficacy as palliative therapy. Based on these results, several groups are exploring 2- and 3-drug combinations using these agents, with and without cisplatin, as initial therapy. The performance status of the patient is a major determinant of which regimen is used, and regimens with lower toxicity profiles are recommended in patients with compromised liver or renal status or serious comorbid conditions.

The regimens effective for urothelial carcinoma (transitional cell) histologies have limited efficacy for patients with nonurothelial (nontransitional cell) carcinomas. These individuals are often treated based on the identified histology (e.g., adenocarcinomas with regimens typically used for colon cancers, and squamous tumors with regimens typically used for tumors originating in the head and neck). However, overall experience with chemotherapy in nonurothelial carcinomas (nontransitional cell tumors) is limited.

Independent of the specific regimen used, patients with metastatic disease are reevaluated after 2 to 3 cycles of chemotherapy, and treatment is continued for 2 more cycles in patients whose disease responds or remains stable. Surgery or radiotherapy may be considered in patients who show a major partial response in an unresectable primary tumor or have a solitary site of residual disease that is resectable after chemotherapy. In selected series, this approach has been shown to afford a survival benefit. If disease is completely resected, 2 additional cycles of chemotherapy can be considered, depending on patient tolerance. Patients for whom surgery or radiotherapy are not considered options are generally treated with chemotherapy for a maximum of 6 cycles, depending on their response.

If no response is noted after 2 cycles or if significant morbidities are encountered, a change in therapy is advised, taking into account the patient's current performance status, extent of disease, and specific prior therapy administered. The same applies to patients who experience systemic relapse after adjuvant chemotherapy. Patients who cannot tolerate cisplatin-based therapy because of medical comorbidities may be considered for treatment with a carboplatin-based regimen or, alternatively, paclitaxel or gemcitabine as a single agent. For palliative therapy, paclitaxel (if it was not used earlier), gemcitabine, or ifosfamide is advised depending on the patient's current status ([Table 3](#)).

### Upper Genitourinary Tract Tumors

Upper tract tumors, including those that originate in the renal pelvis or in the ureter, are relatively uncommon.

### Renal Pelvis

Tumors that develop in the renal pelvis may be identified during evaluation of hematuria or a renal mass. In the latter case, renal pelvic tumors must be distinguished from the more typical adenocarcinomas that originate in the renal parenchyma. These tumors may also be detected during an assessment to pinpoint the source of a positive cytology in the setting of a negative cystoscopy with a retrograde pyelogram.

#### *Workup*

The evaluation of a patient with a suspected renal pelvic tumor should include an IVP, CT urogram, and a retrograde pyelogram with or without ureteroscopy. A CT scan is useful for determining the location of the mass and whether any nodal spread has occurred, and a chest radiograph can help evaluate for possible metastatic disease and assess any comorbid diseases that may be present. Urine cytology obtained from a urine sample or during a cystoscopy may help identify carcinoma cells. Hematologic, renal, and hepatic function should also be evaluated. Additional imaging studies, such as bone scan, may be needed if indicated by the results of these tests or the presence of specific symptoms.

#### *Treatment*

In general, the primary form of treatment for renal pelvic tumors is surgery. If metastatic disease is documented or associated comorbid conditions are present, treatment should include systemic chemotherapy with regimens similar to those used for urothelial (transitional cell) bladder tumors.

Well-differentiated tumors may be managed with a nephroureterectomy with a cuff of bladder, a nephron-sparing procedure through a transureteroscopic approach, or a percutaneous approach to nephroscopy with or without postsurgical intrapelvic chemotherapy or BCG. High-grade tumors or those that are large and invade the renal parenchyma are managed through nephroureterectomy with a cuff of bladder and regional lymphadenectomy.

In the settings of positive upper tract cytology but negative imaging and biopsy studies, treatment remains controversial and appropriate management is currently poorly defined. Frequent monitoring for disease is necessary for these patients.

#### *Follow-up*

Subsequent management is dictated by the extent of disease at surgery. Tumors that are pathologic stage pT0 or pT1 should be followed up with serial cystoscopies at 3-month intervals for the first year and, if negative, every 6 months thereafter. Such tumors should also be followed up with an upper tract imaging study. These studies should include IVP, retrograde pyelogram, or CT or MRI urography, if available, at 1- to 2-year intervals. Other follow-up options may include ureteroscopy at 3- to 12-month intervals if endoscopic resection is considered.

Patients with pT2, pT3, pT4, or nodal disease should be considered for adjuvant chemotherapy, as discussed earlier. Serial evaluations of the urothelial tract, along with imaging studies to exclude metastatic disease, should also be performed.

### Ureteral Tumors

Ureteral tumors may develop de novo or in patients who have undergone successful treatment for superficial tumors that originate in the bladder. The presentation varies as a function of disease extent.

Ureteral tumors may be identified in patients who have a positive cytology with a negative cystoscopy in whom selective catheterization of the ureters is performed. More extensive lesions may result in pain or obstruction.

#### *Workup*

The evaluation is similar to that outlined for tumors that originate in the renal pelvis.

#### *Treatment*

For ureteral tumors that are resectable, the primary management is surgery. The specific procedure required varies depending on the location of the tumor (upper, mid, or distal location) and on disease extent.

Tumors that originate in the upper ureter are treated with nephroureterectomy with a cuff of bladder plus regional lymphadenectomy for high-grade tumors, or with endoscopic resection. A portion of the bladder is removed to ensure complete removal of the entire intramural ureter. Tumors that originate in the mid portion can be divided by grade and size. Small, low-grade tumors can be managed with excision and ureteroureterostomy, endoscopic resection, or nephroureterectomy with a cuff of bladder. Larger, high-grade lesions are managed with nephroureterectomy with a cuff of bladder and regional lymphadenectomy. Distal ureteral tumors may be managed with a distal ureterectomy and reimplantation of the ureter (preferred if

clinically feasible), endoscopic resection, or in some cases, a nephroureterectomy with a cuff of bladder, with the addition of regional lymphadenectomy recommended for high-grade tumors.

#### *Follow-up*

The final pathologic stage is used to guide subsequent management, as is the case for tumors that originate in other sites. No adjuvant therapy is advised for lesions that are pT1 or less, but serial follow-up of the urothelial tracts or remaining unit (as previously described under “Renal Pelvis”) is recommended.

Patients with more extensive disease are advised to undergo systemic adjuvant treatment with chemotherapy, depending on the patient’s anticipated tolerance to the regimen based on comorbidities. The reasons for considering adjuvant therapy are similar to those for tumors that originate in the bladder.

### Urothelial (Transitional Cell) Carcinomas of the Prostate

Urothelial (transitional cell) carcinomas of the prostate represent a distinct entity with a unique staging system. They should be distinguished from urothelial (transitional cell) carcinomas of bladder origin that invade the prostate. Urothelial (transitional cell) carcinomas of the prostate may occur de novo or, more typically, concurrently or after treatment of a bladder cancer. As in the case with tumors originating in other sites of the urothelium, management of prostate urothelial (transitional cell) carcinomas is based on extent of disease with particular reference to the urethra, ductal acini, and stroma.

### Assessment

The evaluation of a suspected urothelial (transitional cell) carcinoma of the prostate includes a digital rectal examination (DRE), cystoscopy with bladder biopsy, and a transurethral biopsy of the prostate that includes the prostatic stroma. Multiple stromal biopsies are also advised and, if the DRE is abnormal, determination of the prostate-specific antigen level and additional needle biopsies are required to exclude primary adenocarcinoma of the prostate. Upper tract collecting system imaging, such as IVP or bilateral retrograde pyelogram, is also recommended.

### Management

Pending histologic confirmation, tumors that are limited to the prostatic urethra with no acinar or stromal invasion can be managed with BCG and transurethral resection of the prostate (TURP), with follow-up similar to that for superficial disease of the bladder. Patients with tumors that invade the ductal acini or stroma should undergo an additional workup with chest radiograph, or CT if necessary, to exclude metastatic disease, and then a cystoprostatectomy with or without urethrectomy should be performed. Alternatively, TUR and BCG may be offered to patients with ductal acini invasion. Adjuvant chemotherapy may be advised for stromal invasion after primary treatment. Recurrences in patients undergoing TURP and BCG therapy are treated with cystoprostatectomy with or without urethrectomy.

### Nonurothelial (Nontransitional Cell) Carcinomas of the Bladder

Approximately 10% of bladder tumors are nonurothelial (nontransitional cell) carcinoma. These pathologic entities include mixed histology, pure

squamous, adenocarcinoma, and small cell tumors. Depending on the pathologic findings, adjuvant chemotherapy may or may not be recommended. Patients with nonurothelial invasive disease are generally treated with cystectomy, although those with certain urachal tumors require complete urachal resection or may be appropriately treated with partial cystectomy. In patients with nonurothelial carcinomas of any stage, no data support the use of adjuvant chemotherapy, although the risk for relapse may be high.

Some of the general principles of management applicable to urothelial (transitional cell) carcinomas are appropriate with minor variations. These variations are documented on [BL-C](#).

### Summary

Urothelial tumors represent a spectrum of diseases with a range of prognoses. After a tumor is diagnosed anywhere within the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location and at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management because most recurrences are superficial and can be treated endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing each patient's likelihood of cure and chance for organ preservation.

For patients with more extensive disease, newer treatments typically involve combined modality approaches using recently developed surgical procedures, or 3-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate

in all cases, they offer the promise of an improved quality of life and prolonged survival.

Finally, within the category of metastatic disease, several new agents have been identified that seem superior to those currently considered standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.

**Table 2. Principles of Pathology Management: Malignancy Grading of Bladder Carcinoma: Old and New Systems<sup>a,b</sup>**

Modified Bergkvist 1987	WHO 1973	WHO/ISUP 1998 Consensus WHO, 2004
Papilloma grade 0	Papilloma	Papilloma
Papilloma with atypia grade 1	TCC grade 1	Papillary urothelial neoplasm of low malignant potential
Urothelial carcinoma grade 2A	TCC grade 1	Urothelial carcinoma, low-grade
Urothelial carcinoma grade 2B	TCC grade 2	Urothelial carcinoma, high-grade
Urothelial carcinoma grade 3	TCC grade 3	Urothelial carcinoma, high-grade

<sup>a</sup>From Droller MJ. Bladder Cancer, Current Diagnosis and Treatment. Totowa (NJ): Humana Press, 2001.

<sup>b</sup>Several classifications have been proposed for grading of tumors of the bladder epithelium. Because they are in general usage, the current NCCN guidelines for bladder and upper tract cancers continue to use the World Health Organization (WHO) histologic classification of tumors of the urinary tract from 1973. However, a revised classification has been adopted by numerous organizations, including the WHO in their

most recent publication in 2004. This classification has also been adopted by the College of American Pathologists, the American Society of Clinical Pathology, and the International Society of Urologic Pathologists.

Please note several major changes in this classification. First, the term *transitional cell* is changed to *urothelial*. Also, dysplastic changes of the urothelium without invasion are now classified either as carcinoma in situ or as dysplasia without specification of mild, moderate, or severe. Any dysplastic, flat, noninvasive lesion that does not meet the criteria of CIS is referred to as *dysplasia*.

The criteria used for the new classification system are more specific than those for the 1973 WHO classification system. The entire classification system, including the range of types of tumors, is presented on pages 90–91 of the new WHO classification of tumors.

**References**

Busch C, Hawes D, Johansson S, Cote R. Pathologic assessment of bladder cancer and pitfalls in staging. In: Droller MJ, ed. Bladder Cancer, Current Diagnosis and Treatment. Totowa (NJ): Humana Press, 2001:149–182.

Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002;441:105–108.

Check W. Bladder biopsies in step with clinical side. CAP Today (College of American Pathologists) 2004;18:43–54.

Eble JN, Sauter G, Epstein JI, et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC (International Agency for Research on Cancer) Press, 2004.

Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–1448.

15. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumor Pathology. 4th series. Washington (DC): American Registry of Pathology, 2004.

**Table 3. Combination Chemotherapy Regimens**

Regimen	Dosage	
<b>M-VAC</b> <sup>35</sup>	Methotrexate	30 mg/m <sup>2</sup> on days 1, 15, 22
	Vinblastine	3 mg/m <sup>2</sup> on days 2, 15, 22
	Doxorubicin	30 mg/m <sup>2</sup> on day 2
	Cisplatin	70 mg/m <sup>2</sup> on day 2'
<b>MCV</b> <sup>36,37</sup>	Methotrexate	30 mg/m <sup>2</sup> on days 1, 8
	Vinblastine	3 mg/m <sup>2</sup> on days 1, 8
	Cisplatin	100 mg/m <sup>2</sup> on day 2
<b>Gemcitabine/ Cisplatin</b> <sup>38,39</sup>	Gemcitabine*	1000 mg/m <sup>2</sup> on days 1, 8, 15 of 28-day cycle
	Cisplatin	70 mg/m <sup>2</sup> on day 2

\*This dose should not be combined with radiation.

**Table 4. Relapse or Noncomplete Response**

<b>Second-line Chemotherapy</b>
Ifosfamide
Gemcitabine
Paclitaxel (if no prior paclitaxel)

**Disclosures for the NCCN Bladder Cancer Guidelines Panel**

At the beginning of each panel meeting to develop NCCN guidelines, panel members disclosed financial support they have received in the form of research support, advisory committee membership, or speakers' bureau participation. Members of the panel participating in updating the 2007 guideline indicated that they have received no support from industry.

The panel did not regard any potential conflicts of interest as sufficient reason to disallow participation in panel deliberations by any member.

## References

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta (GA): American Cancer Society, 2006.
2. Brodsky GL. Pathology of bladder carcinoma. *Hematol Oncol Clin North Am* 1992;6:59–80.
3. Kakizoe T, Matsumoto K, Andoh M, et al. Adenocarcinoma of urachus: report of 7 cases and review of literature. *Urology* 1983;21:360–366.
4. Herr HW. Urachal carcinoma: the case for extended partial cystectomy. *J Urol* 1994;151:365–366.
5. Reuter V. Pathology of bladder cancer: assessments of prognostic variables in response therapy. *Semin Oncol* 1990;17:524–532.
6. Herr HW, Shipley WU, Bajorin DF. Cancer of the bladder. In: DeVita VT, Hellman S, Rosenberg SA, eds. *Cancer: Principles and Practice of Oncology*, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
7. Hall RR, Parmar MK, Richards AB, Smith PH. Changes in cystoscopic follow up in patients with bladder cancer and adjuvant intravesical chemotherapy. *BMJ* 1994;308:257–260.
8. Greene FL, Page DL, Fleming ID, et al., eds. *AJCC Cancer Staging Manual*, 6th ed. New York: AJCC Springer-Verlag, 2002.
9. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. *Am J Surg Pathol* 1998;22:1435–1448.
10. Murphy WM. Classification of urothelial neoplasms; one, two, three, around we go. *Urol Oncol* 2001;6:69–71.
11. Smith JA Jr, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). *J Urol* 1999;162:1697–1701.
12. Herr H, Sogni PC. Does early cystectomy improve survival of patients with high-risk superficial bladder tumors? *J Urol* 2001;166:1296–1299.
13. Tanimoto A, Yuasa Y, Imai Y, et al. Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT. *Radiology* 1992;185:741–747.
14. Kim B, Semelka RC, Ascher SM, et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhancing imaging. *Radiology* 1994;193:239–245.
15. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 2003;349:859–866.
16. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatin based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. *Eur Urol* 2004;45:297–303.
17. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. *J Urol* 2004;171:561–569.
18. Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. *Lancet Oncol* 2002;3:738–747.
19. Scher HI. Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. *Semin Oncol* 1990;17:555–565.
20. Kata EJ, Herr H. The role of transurethral resection for muscle invasive bladder carcinoma [abstract]. *J Urol* 1993;149:316A. Abstract.

21. Sweeney P, Kursh ED, Resnick MI. Partial cystectomy. *Urol Clin North Am* 1993;19:701–711.
22. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of RTOG 89-03. *J Clin Oncol* 1998;16:3576–3583.
23. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. *Urology* 2002;60:62–67.
24. Rotman M, Aziz H. Concomitant continuous infusion chemotherapy and radiation. *Cancer* 1990;65:823–835.
25. Russell KJ, Boileau MA, Higano C, et al. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. *Int J Radiat Oncol Biol Phys* 1990;19:693–699.
26. Russell KJ, Boileau MA, Ireton RC, et al. Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study. *Radiology* 1988;167:845–848.
27. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. *J Clin Oncol* 1993;11:2150–2157
28. Orsatti M, Curotto A, Canobbio L, et al. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. *Int J Radiat Oncol Biol Phys* 1995;33:173–178.
29. Zietman AL, Shipley WU, Kaufman DS, et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. *J Urol* 1998;160:1673–1677.
30. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol No. 30924. *J Clin Oncol* 2001;19:2638–2646.
31. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. *J Urol* 1996;155:495–500.
32. Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract a Northern California Oncology Group study. *J Clin Oncol* 1985;3:1463–1470.
33. Lorusso V, Manzione L, de Vita F, et al. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. *J Urol* 2000;164:53–56.
34. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol* 2000;18:3068–3077.

### Recommended Reading

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. *Eur Urol* 2005;48:189–199; discussion 199–201.

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data

advanced bladder cancer (ABC) meta-analysis collaboration. *Eur Urol* 2005;48:202–205; discussion 205–206.

Bajorin DF, McCaffrey JA, Dodd PM, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. Final report of a phase II trial evaluating two dosing schedules. *Cancer* 2000;88:1671–1678.

Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. *J Urol* 1999;161:1494–1497.

Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1996;14:2901–2907.

Czito B, Zietman A, Kaufman D, et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. *J Urol* 2004;172:1271–1275.

Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. *J Urol* 2001;165:1111–1116.

Dodd PM, McCaffrey JA, Herr H, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. *J Clin Oncol* 1999;17:2546–2552.

Donat SM, Genega EM, Herr HW, et al. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. *J Urol* 2001;165:1117–1120.

Fleischmann A, Thalmann GN, Markwalder R, et al. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. *J Clin Oncol* 2005;23:2358–2365.

Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated

superficial transitional cell carcinoma of the bladder. *Cancer* 1999;86:2337–2345.

Ghoneim MA, Abol-Enein H. Lymphadenectomy with cystectomy: is it necessary and what is its extent? *Eur Urol* 2004;46:457–461.

Giannopoulos A, Manousakas T, Gounari A, et al. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. *J Urol* 2001;166:470–475.

Gospodarowicz MK. Locally advanced bladder cancer. Radiation therapy and chemotherapy. *Eur Urol* 1998;33(Suppl 4):27–31.

Herr HW. Extravesical tumor relapse in patients with superficial bladder tumors. *J Clin Oncol* 1998;16:1099–1102.

Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. *J Clin Oncol* 2001;19:89–93.

Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. *J Clin Oncol* 2004;22:2781–2189.

Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. *J Urol* 2005;174:2134–2137.

Hollenbeck BK, Taub DA, Miller DC, et al. The regionalization of radical cystectomy to specific medical centers. *J Urol* 2005;174:1385–1389; discussion 1389.

Hussain MH, Glass TR, Forman J, et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group study. *J Urol* 2001;165:56–61.

Jakse G, Hall R, Bono A. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU group phase II protocol 30861. *Eur Urol* 2001;40:144–150.

Lamm DL. Preventing progression and improving survival with BCG maintenance. *Eur Urol* 2000;37(Suppl 1):9–15.

Leissner J, Hohenfellner R, Thuroff JW, et al. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. *BJU Int* 2000;85:817–823.

Logothetis C, Swanson D, Amato R, et al. Optimal delivery of perioperative chemotherapy: preliminary results of randomized, prospective, comparative trial of pre-operative and postoperative chemotherapy for invasive bladder carcinoma. *J Urol* 1996;155:1241–1245.

Montie JE, Smith DC, Sandler HM. Carcinoma of the bladder. In: Abeloff MD, Armitage JO, Lichter AS, ed. *Clinical Oncology*, 2nd ed. New York: Churchill Livingstone, 2000:2059–2084.

Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. *J Clin Oncol* 2002;20:3061–3071.

Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol* 2001;19:666–675.

Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. *J Urol* 2004;171:2186–2190.

von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *J Clin Oncol* 2005;23:4602–4608.

Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. *Urology* 2001;58:380–385.

Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. *J Urol* 2003;170:1772–1776.